$HELP

Glavine Paul purchased $1.0M of HELP

Glavine Paul (Chief Growth Officer) purchased 90,000 shares of CYBIN INC. (HELP) at $11.59 ($1.04M total) on 2026-08-31.

Original reporting
SEC EDGAR · Glavine Paul
Published Sep 9, 2026, 3:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 3:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$HELP
Bullish
high confidence
Mentioned
$HELP
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HELPBullishMed
01

Why it matters

The $1.04M purchase by the Chief Growth Officer adds to his existing large stake, indicating strong confidence in Cybin's prospects.

02

Market read

Insider buying of this magnitude can trigger short‑term buying interest and may influence analyst sentiment.

03

What to watch

Potential upcoming clinical trial results or regulatory filings not disclosed in the Form 4.

Relevance 7/10Novelty 7/10Timing: transaction dated 2026-08-31, filed 2026-09-09

Background

Form 4 filings disclose insider trades; C‑level purchases are closely watched by traders for sentiment cues.

Company-level read

Ticker impact

$HELPBullishHigh confidence
Context

Chief Growth Officer Glavine Paul bought 90,000 shares of Cybin Inc. for $1.04M, increasing his stake to over 4 million shares.

Expected impact

Potential modest upward pressure as market absorbs the insider buying signal.

Evidence & confidence

C‑level insider purchases are viewed as strong bullish cues, especially when the transaction size exceeds $1M.

Market effects

May boost sentiment for biotech and pharma sector peers as insider confidence spreads.

Limited to US biotech market; no broader regional effect.

Minimal global impact beyond sector perception.

Counterpoint

Insider buying could be a window dressing move ahead of upcoming dilution or negative news.

Key entities

  • Cybin Inc.

    Biopharma company developing psychedelic therapeutics.

  • Glavine Paul

    Chief Growth Officer of Cybin Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HELPMed

Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights

Helus Pharma (Nasdaq: HELP) reported fiscal Q1 2027 results for the quarter ended June 30, 2026. Cash was $166.4M. Net loss was $47.8M vs $24.6M a year earlier. The company said Phase 3 APPROACH enrollment for HLP003 in MDD is complete with topline data expected in Q4 2026, and a DDI study showed no meaningful PK interaction. It also completed a $50M underwritten offering in June 2026.

$HELPMed

Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule

Helus Pharma (Nasdaq: HELP) said it completed enrollment in its Phase 3 APPROACH study of HLP003, an investigational adjunctive treatment for major depressive disorder, ahead of schedule. The company reported 223 enrolled participants and expects topline data in Q4 2026. Phase 2 results cited include ~23-point MADRS reduction and 100% response/71% remission.